FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281674954> ?p ?o ?g. }

• W4281674954 endingPage "e548" @default.
• W4281674954 startingPage "e536" @default.
• W4281674954 abstract "Pompe disease is a rare, progressive neuromuscular disorder caused by deficiency of lysosomal acid α-glucosidase (GAA) and subsequent glycogen accumulation. Avalglucosidase alfa, a recombinant human GAA enzyme replacement therapy designed for increased cellular uptake and glycogen clearance, has been studied for long-term efficacy and safety in patients with late-onset Pompe disease (LOPD). Here we report up to 6.5 years' experience with avalglucosidase alfa during the NEO1 and NEO-EXT studies.NEO1 participants with LOPD, either treatment-naïve (Naïve Group) or receiving alglucosidase alfa for ≥9 months (Switch Group), received avalglucosidase alfa (5, 10, or 20 mg/kg every other week [qow]) for 6 months before entering NEO-EXT and continued their NEO1 dose until all proceeded with 20 mg/kg qow. Safety and efficacy, a pre-specified exploratory secondary outcome, were assessed; slopes of change for efficacy outcomes were calculated from a repeated mixed-measures model.Twenty-four participants enrolled in NEO1 (Naïve Group, n=10; Switch Group, n=14); 21 completed and 19 entered NEO-EXT; in February 2020, 17 participants remained in NEO-EXT, with data up to 6.5 years. Avalglucosidase alfa was generally well-tolerated during NEO-EXT, with a safety profile consistent with that in NEO1. No deaths or treatment-related life-threatening serious adverse events occurred. Eighteen participants developed anti-drug antibodies without apparent impact on clinical outcomes. No participants who were tested developed immunoglobulin E antibodies. Upright forced vital capacity (FVC) %predicted remained stable in most participants, with slope estimates (95% confidence intervals) of -0.473/year (-1.188, 0.242) and -0.648/year (-1.061, -0.236) in the Naïve and Switch Groups, respectively. Six-minute walk test (6MWT) %predicted was also stable for most participants, with slope estimates of -0.701/year (-1.571, 0.169) and -0.846/year (-1.567, -0.125) for the Naïve and Switch Groups, respectively. Improvements in 6MWT distance were observed in most participants aged <45 years at NEO1 enrollment, in both the Naïve and Switch Groups.Avalglucosidase alfa was generally well-tolerated for up to 6.5 years in adult participants with LOPD either naïve to alglucosidase alfa or who had previously received alglucosidase alfa for ≥9 months.Classification of Evidence: This study provides Class IV evidence of long-term tolerability and sustained efficacy of avalglucosidase alfa in patients with LOPD after up to 6.5 years." @default.
• W4281674954 created "2022-06-13" @default.
• W4281674954 creator A5004880821 @default.
• W4281674954 creator A5005521984 @default.
• W4281674954 creator A5013023361 @default.
• W4281674954 creator A5023248855 @default.
• W4281674954 creator A5026847169 @default.
• W4281674954 creator A5027654969 @default.
• W4281674954 creator A5028242117 @default.
• W4281674954 creator A5030669499 @default.
• W4281674954 creator A5031038377 @default.
• W4281674954 creator A5037775852 @default.
• W4281674954 creator A5038421269 @default.
• W4281674954 creator A5039404447 @default.
• W4281674954 creator A5039905544 @default.
• W4281674954 creator A5046451291 @default.
• W4281674954 creator A5051045476 @default.
• W4281674954 creator A5054035846 @default.
• W4281674954 creator A5064590301 @default.
• W4281674954 creator A5067876029 @default.
• W4281674954 creator A5072518895 @default.
• W4281674954 creator A5074845584 @default.
• W4281674954 creator A5081289330 @default.
• W4281674954 creator A5087761286 @default.
• W4281674954 creator A5088683724 @default.
• W4281674954 date "2022-08-02" @default.
• W4281674954 modified "2023-10-18" @default.
• W4281674954 title "Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease" @default.
• W4281674954 cites W1980761371 @default.
• W4281674954 cites W2018248741 @default.
• W4281674954 cites W2022885290 @default.
• W4281674954 cites W2051386832 @default.
• W4281674954 cites W2055655054 @default.
• W4281674954 cites W2055864845 @default.
• W4281674954 cites W2083805206 @default.
• W4281674954 cites W2087686765 @default.
• W4281674954 cites W2095643828 @default.
• W4281674954 cites W2099449365 @default.
• W4281674954 cites W2102023102 @default.
• W4281674954 cites W2108678383 @default.
• W4281674954 cites W2119013995 @default.
• W4281674954 cites W2135690636 @default.
• W4281674954 cites W2469663448 @default.
• W4281674954 cites W2488430149 @default.
• W4281674954 cites W2903654923 @default.
• W4281674954 cites W2949405692 @default.
• W4281674954 cites W2951951272 @default.
• W4281674954 cites W2981219681 @default.
• W4281674954 cites W3033985139 @default.
• W4281674954 cites W3128483827 @default.
• W4281674954 cites W3211462560 @default.
• W4281674954 cites W4211025614 @default.
• W4281674954 cites W4230776534 @default.
• W4281674954 cites W4245666729 @default.
• W4281674954 doi "https://doi.org/10.1212/wnl.0000000000200746" @default.
• W4281674954 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35618441" @default.
• W4281674954 hasPublicationYear "2022" @default.
• W4281674954 type Work @default.
• W4281674954 citedByCount "9" @default.
• W4281674954 countsByYear W42816749542022 @default.
• W4281674954 countsByYear W42816749542023 @default.
• W4281674954 crossrefType "journal-article" @default.
• W4281674954 hasAuthorship W4281674954A5004880821 @default.
• W4281674954 hasAuthorship W4281674954A5005521984 @default.
• W4281674954 hasAuthorship W4281674954A5013023361 @default.
• W4281674954 hasAuthorship W4281674954A5023248855 @default.
• W4281674954 hasAuthorship W4281674954A5026847169 @default.
• W4281674954 hasAuthorship W4281674954A5027654969 @default.
• W4281674954 hasAuthorship W4281674954A5028242117 @default.
• W4281674954 hasAuthorship W4281674954A5030669499 @default.
• W4281674954 hasAuthorship W4281674954A5031038377 @default.
• W4281674954 hasAuthorship W4281674954A5037775852 @default.
• W4281674954 hasAuthorship W4281674954A5038421269 @default.
• W4281674954 hasAuthorship W4281674954A5039404447 @default.
• W4281674954 hasAuthorship W4281674954A5039905544 @default.
• W4281674954 hasAuthorship W4281674954A5046451291 @default.
• W4281674954 hasAuthorship W4281674954A5051045476 @default.
• W4281674954 hasAuthorship W4281674954A5054035846 @default.
• W4281674954 hasAuthorship W4281674954A5064590301 @default.
• W4281674954 hasAuthorship W4281674954A5067876029 @default.
• W4281674954 hasAuthorship W4281674954A5072518895 @default.
• W4281674954 hasAuthorship W4281674954A5074845584 @default.
• W4281674954 hasAuthorship W4281674954A5081289330 @default.
• W4281674954 hasAuthorship W4281674954A5087761286 @default.
• W4281674954 hasAuthorship W4281674954A5088683724 @default.
• W4281674954 hasBestOaLocation W42816749541 @default.
• W4281674954 hasConcept C126322002 @default.
• W4281674954 hasConcept C197934379 @default.
• W4281674954 hasConcept C2779134260 @default.
• W4281674954 hasConcept C2779969927 @default.
• W4281674954 hasConcept C71924100 @default.
• W4281674954 hasConceptScore W4281674954C126322002 @default.
• W4281674954 hasConceptScore W4281674954C197934379 @default.
• W4281674954 hasConceptScore W4281674954C2779134260 @default.
• W4281674954 hasConceptScore W4281674954C2779969927 @default.
• W4281674954 hasConceptScore W4281674954C71924100 @default.
• W4281674954 hasIssue "5" @default.
• W4281674954 hasLocation W42816749541 @default.

• next